- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT03502434
Um estudo de teste de remendo de insulto repetido (RIPT) avaliando o potencial de sensibilização da solução SM04755 tópica em voluntários saudáveis
Um estudo de Fase 1, Centro Único, Teste de Remendo Insulto Repetido (RIPT) avaliando o potencial de sensibilização da solução SM04755 tópica
This is a single center, randomized, controlled, within subject comparison, single dose study to determine the sensitization potential of SM04755 solution on normal skin under semi-occlusive patch conditions.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
This Phase 1, Repeat Insult Patch Test (RIPT) study is a single-center study of topical SM04755 solution repetitively applied to skin of healthy volunteers. This study will assess the potential of the Test Materials to induce contact sensitization as measured by treatment emergent adverse events (TEAEs), Reaction Grade and Investigator assessment of irritation and sensitization.
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Virginia
-
Lynchburg, Virginia, Estados Unidos, 24503
- Research Site
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Healthy adult males and females at least 18 years of age
- Subjects of any Fitzpatrick skin type or race provided their degree of skin pigmentation does not, in the Investigator or designee's opinion, interfere with study assessments
- Subject has no signs of irritation (i.e., a Reaction Grade of "0") at patch application sites on the back prior to the initial patch application on Day 1
- Subject must have read, understood, and signed the informed consent form prior to any study-related procedure being performed
- Subject is willing and able to comply with all scheduled study visits, urine pregnancy tests (if applicable), contraception requirements (male and female), and other study requirements
- Subject is willing to avoid extensive sun exposure, phototherapy, or use of a tanning salon for the duration of the study
Exclusion Criteria:
- Women who are pregnant or lactating
- Women of childbearing potential who are sexually active and are not willing to use a highly effective method of birth control during the study period that includes double barrier, IUD, or hormonal contraceptive combined with single barrier, or abstinence
- Women of childbearing potential who have had unprotected sexual intercourse within 30 days prior to Day 1
- Males who are sexually active and not willing to use a condom, and have a partner who is capable of becoming pregnant, if neither has had surgery to become sterilized, and/or who are not willing to use double barrier or whose partner is not using a highly effective method of birth control (e.g., IUD, or hormonal contraception combined with single barrier)
- Subject has any skin condition that, in the Investigator's opinion, could interfere with the study assessments or put the subject at undue risk by study participation
- Subject has severe atopic dermatitis/eczema, psoriasis or chronic asthma
- Subject has tattoos, excessive hair, moles, scarring, etc. which would interfere with patching
- Subject has a history of sensitivity to any component of any of the Test Materials
- Use of any of the following medications:
- Systemic or topical glucocorticoids within 4 weeks prior to Day 1
- Systemic or topical analgesics (e.g., NSAIDs, high dose aspirin, etc.) within 1 week prior to Day 1. Note: Daily use of ≤325 mg of aspirin for cardiovascular disease or prophylaxis is allowed. Maximum daily use of Tylenol ≤3000 mg is allowed.
- Antihistamines within 1 week prior to Day 1. Note: H2 blockers such as Pepcid, Zantac, and Tagamet are permitted.
- Anti-inflammatories within 1 week prior to Day 1
- Immunosuppressant medications (e.g., TNF-alpha inhibitors, topical tacrolimus, etc.) within 4 weeks prior to Day 1 (or within 6 half-lives prior to Day 1 for biologics)
- Subject has had previous treatment with SM04755
- Subject has an active infection of hepatitis B or C or human immunodeficiency virus (HIV) infection as determined by an interview
- Participation in a clinical research trial that included the receipt of an investigational product or any experimental therapeutic procedure within 8 weeks prior to Screening, or planned participation in any such trial; the last date of participation in the trial, not the last date of receipt of investigational product, must be at least 8 weeks prior to Screening
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: 90 mg/mL SM04755 in water
90 mg/mL SM04755 in water applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Experimental: 90 mg/mL SM04755 in aqueous Vehicle
90 mg/mL SM04755 in aqueous Vehicle applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Experimental: 90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol)
90 mg/mL SM04755 in aqueous Vehicle (without Benzyl Alcohol) applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Outro: Vehicle
Aqueous Vehicle applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Outro: White petrolatum
White petrolatum (Negative control) applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
|
Outro: Sodium lauryl sulfate
Sodium lauryl sulfate (SLS 0.5%) (Positive control) applied via patches |
Healthcare professional-applied patches to subjects during the Induction Period on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19, and during the Challenge Period on Day 36. Patches are to be worn by the subject for approximately 48-72 hours before removal and reaction grading. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Potencial de sensibilização de contato do material de teste medido pelo tratamento emergente
Prazo: Linha de base até o dia 40 (ou durante o período de observação para TEAEs)
|
Linha de base até o dia 40 (ou durante o período de observação para TEAEs)
|
|
|
Potencial de sensibilização de contato do material de teste conforme medido pela avaliação do investigador de irritação e sensibilização
Prazo: Linha de base até o dia 40
|
Linha de base até o dia 40
|
|
|
Contact sensitization potential of Test Material as measured by Reaction Grade
Prazo: Baseline to Day 38-40
|
Reaction Grade is measured on a 5-point scale from zero to four (zero = no sign of irritation and 4 = Erythema with edema and blistering) |
Baseline to Day 38-40
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Yusuf Yazici, M.D., Biosplice Therapeutics, Inc.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças musculoesqueléticas
- Doenças Musculares
- Ferimentos e Lesões
- Lesões de tendão
- Tendinopatia
- Compostos de enxofre
- Produtos químicos orgânicos
- Lipídios
- Hidrocarbonetos
- Álcoons
- Alkanesulfonatos
- Ácidos alcanesulfônicos
- Ácidos sulfônicos
- Ácidos de enxofre
- Álcoois gordurosos
- Dodecanol
- Petrolato
- Lauril Sulfato de Sódio
Outros números de identificação do estudo
- SM04755-TOP-02
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .